登录 | 注册    微信公众号  
搜索
 > 【E-Selectin】

E-Selectin信息

英文名称:Selectin E
中文名称:选择素-E
靶点别称:LECAM2,ELAM1,Endothelial leukocyte adhesion molecule 1,ELAM-1,SELE,Selectin E,CD62 Antigen-Like Family Member E,Endothelial Adhesion Molecule 1,Leukocyte-Endothelial Cell Adhesion Molecule 2,CD62E Antigen,CD62E,ESEL,ELAM,E-Selectin,Leukocyte Endothelial Cell Adhesion Molecule 2
上市药物数量:0
临床药物数量:3
最高研发阶段:临床三期

E-Selectin产品列表

产品库
物种
属性
货号 物种 产品描述 蛋白结构 纯度 活性
CDE-H5222
Human
Human E-Selectin / CD62E Protein, His Tag
CDE-H5250
Human
Human CD62E E-Selectin Protein, With C-Fc Tag
 
评论(0)
 

E-Selectin 分子别名

SELE,RP1-117P20.2,CD62E,ELAM1,ESEL,LECAM2,E-Selectin

E-Selectin 分子背景

E-Selectin is also known as CD62 antigen-like family member E (CD62E), endothelial-leukocyte adhesion molecule 1 (ELAM-1), or leukocyte-endothelial cell adhesion molecule 2 (LECAM2), a member of the Selectin family, is a 107-115 kDa cell surface glycoprotein. It is transiently expressed on vascular endothelial cells in response to IL-1β and TNFα. E selectin has a cassette structure: an N-terminal, C-type lectin domain, an EGF (epidermal-growth-factor)-like domain, 6 Sushi domain (SCR repeat) units, a transmembrane domain (TM) and an intracellular cytoplasmic tail (cyto). During inflammation, E-selectin plays an important part in recruiting leukocytes to the site of injury. The local release of cytokines IL-1 and TNF-α by damaged cells induces the over-expression of E-selectin on endothelial cells of nearby blood vessels. E-selectin mediates the adhesion of tumor cells to endothelial cells, by binding to E-selectin ligands expressed by neutrophils, monocytes, eosinophils, memory-effector T-like lymphocytes, natural killer cells or cancer cells. Furthermore, a number of studies have reported that levels of E-Selectin may be elevated in subjects with a variety of pathological conditions.

E-Selectin 前沿进展

E-Selectin临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
E-selectin targeting humanized antibody (LifeArc) 临床一期 Lifearc 脓毒病, 成人呼吸窘迫综合征 详情
GMI-1359 GMI-1359 临床一期 Glycomimetics Pharmaceutical 乳腺癌, 转移性乳腺癌 详情
Uproleselan GMI-1271; APL-106 临床三期 Glycomimetics Pharmaceutical 多发性骨髓瘤, 急性髓细胞样白血病, 静脉血栓形成 详情

消息提示

请输入您的联系方式,再点击提交!

确定